

October 21, 2010

Capital and Business Alliance on R&D for Biosimilars

We hereby give notice that Nichi-Iko Pharmaceutical Co., Ltd. (headquarters: Sogawa, Toyama City; hereafter "Nichi-Iko") and Aprogen Inc. (headquarters: Daejeon, Korea; hereafter "Aprogen") have today signed a capital / business alliance agreement on research and development for Biosimilars

Aprogen is a bio venture company which receives a high level of support from Tm[]TJET EMC21, 20tes